Teva Pharmaceutical Industries Limited

TEVA

US8816242098

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 18/07/2024 am IST			5-day change	1st Jan Change
16.38 ^USD	-1.62%		-3.53%	+56.90%

01/07	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
01/07	Sector Update: Health Care Stocks Slipping in Afternoon Trading	MT

Teva Pharmaceutical Is Not Seeking Acquisitions

January 08, 2018 at 10:30 am IST

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is not planning any major acquisition.

Latest news about Teva Pharmaceutical Industries Limited

Sector Update: Health Care Stocks Retreat Late Afternoon	02/07	MT
Sector Update: Health Care Stocks Slipping in Afternoon Trading	01/07	MT
Teva Pharmaceuticals Faces FTC Probe on Patent Listings	01/07	MT
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity	01/07	MT
Teva Pharmaceutical Faces FTC Investigation for Patents, Washington Post Says	01/07	DJ
Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity	01/07	MT
Teva Pharmaceuticals Faces FTC Probe on Patent Listings	01/07	MT
Teva Pharmaceuticals Faces FTC Probe on Patent Listings	01/07	MT
FTC Opens Investigation Into Teva Pharmaceuticals	01/07	MT
FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports	01/07	MT
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz	01/07	MT
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses	28/06	CI
Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating	27/06	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	25/06
Teva Pharmaceutical Pays $750 Million to Resolve Tax-Related Litigation	25/06	MT
Teva settles tax dispute in Israel with $750 mln payment	25/06	RE
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020	25/06	CI
Teva Pharmaceutical Launches Generic Victoza in US	24/06	MT
Teva Pharmaceutical Industries Limited Announces Launch of Authorized Generic of Victoza® (Liraglutide Injection 1.8Mg), in the United States	24/06	CI
Teva Pharmaceutical Industries 'Well-Positioned' for Further Growth, UBS Says	21/06	MT
Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva...	14/06
Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	14/06	MT
Transcript : Teva Pharmaceutical Industries Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM	11/06
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating	05/06	MT
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill	30/05	MT

Chart Teva Pharmaceutical Industries Limited

Duration

Period

Chart Teva Pharmaceutical Industries Limited

More charts

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 03:11 pm IST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 03, 2023 at 12:49 am IST

More Strategies

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.38 USD

Average target price

18.94 USD

Spread / Average Target

+15.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	+56.90%	1.86TCr
ELI LILLY AND COMPANY	+55.35%	82TCr
NOVO NORDISK A/S	+32.36%	60TCr
JOHNSON & JOHNSON	-0.10%	38TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	31TCr
ASTRAZENECA PLC	+16.49%	25TCr
NOVARTIS AG	+14.94%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr

Other Pharmaceuticals

Teva Pharmaceutical Industries Limited

Equities

TEVA

US8816242098

Pharmaceuticals

Teva Pharmaceutical Is Not Seeking Acquisitions

Latest news about Teva Pharmaceutical Industries Limited

Chart Teva Pharmaceutical Industries Limited

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Teva Pharmaceutical Industries Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals